Milnubes / Curiosity, with sourcesBotany · Culture · Science
milnubes.
Milnubes/Encyclopedia/SCRA
Cannabinoid atlas / Reference entry
SCRA
Other synthetic agonists

Synthetic cannabinoid receptor agonists

A heterogeneous family that needs its own entry. The word cannabinoid does not imply that these compounds resemble CBD in effects, composition or risk. JWH-018 and MDMB-4en-PINACA are examples, not synonyms for the entire family.

Documentary review: Milnubes editorial desk · assisted by AI
Empty glass tubes in a black rack against a white wall.
Stock photograph providing context for this entry. It does not document a trial, participant, identified product or AGONISTAS-SINTETICOS result.
Evidence map

Mixed evidence by question. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

Many synthetic agonists have structures unlike plant cannabinoids. Commercial names such as Spice or K2 refer to changing mixtures, not a molecule with a constant composition.

Source · EUDA: synthetic cannabinoids in Europe

Terms associated with this entry: SCRA, SCRAs, synthetic cannabinoid receptor agonists, agonistas sintéticos de los receptores cannabinoides.

One family, many identities

This entry is a classification warning. Analysis needs to identify the actual compound: a family name cannot tell us how much a product contains or predict its effects. Synthetic does not itself mean medicinal; that status depends on an assessed and authorised product.

What has been studied

No established clinical benefit

The review of MDMB-4en-PINACA identifies no authorised therapeutic use. Receptor research does not establish a clinical benefit for products sold under commercial names.

Source · WHO: MDMB-4en-PINACA critical review (2020)

Risks and gaps

The European assessment of MDMB-4en-PINACA documents serious poisonings and considers neurological, cardiovascular and respiratory risks. This concerns a particular substance, not an identical risk rate for every agonist.

Source · EUDA: MDMB-4en-PINACA risk assessment

Mixtures and their ingredients can change. Recognising packaging or a herbal appearance does not verify composition. Uncertainty is part of the problem, not an indication of safety.

Source · EUDA: synthetic cannabinoids in Europe

Documented forms

Detected herbal mixtures and liquidsEuropean alert systems have described herbal mixtures, liquids and other carriers containing synthetic agonists. These are surveillance findings; they validate no route of use.
Source · EUDA: MDMB-4en-PINACA risk assessment

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

These compounds do not belong on a supposed scale of mild and strong cannabinoids. Identity, analytical quality and toxicity data are prior questions. This entry does not present them as wellness options or propose consumption comparisons.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. EUDA: synthetic cannabinoids in Europe · Official body
  2. EUDA: MDMB-4en-PINACA risk assessment · Official body
  3. WHO: MDMB-4en-PINACA critical review (2020) · Official body

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.